Akari (AKTX), the company’s executive leadership team, investigators, and independent scientific investors will hold a Research & Development Day April 24th. Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH) will be presented by Dr. Anita Hill. Key Opinion Leaders Dr. Robert Snelgrove and Professir Arne Skerra will be also be available for questions following their presentations.
Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH) will be presented by Dr Anita Hill, the lead investigator in the study. Dr Hill is a Consultant Haematologist and Honorary Clinical Associate Professor at Leeds Teaching Hospital, which is one of the world’s largest treatment centers for PNH patients.
Results from the pre-clinical development program targeting new disease opportunities for our lead compound Coversin, focusing on its unique dual leukotriene B4 (LTB4)/C5 activity will be presented by Dr Robert Snelgrove, National Heart and Lung Institute, Imperial College London whose particular expertise lies in LTB4 and lung inflammation.
New data on the pre-clinical pipeline, including the once-weekly subcutaneous formulation of Coversin, will be presented by Professor Arne Skerra, Professor of Biological Chemistry at the University of Munich and Chairman of XL-protein GmbH.
To register and access the simulcast please click here.